SCHEMBL14933658

SCHEMBL14933658

O=[N+]([O-])c1ccc(Nc2cc(F)ccc2F)c2nonc12

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.59
KMT2A Q03164 10/20 0.59
MYC P01106 8/20 0.59
IDO1 P14902 6/20 0.59
POLB P06746 1/20 0.58
GAA P10253 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MAX P61244 4/20 0.53
PSMD14 O00487 1/20 0.53
MAPT P10636 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
USP2 O75604 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
TDO2 P48775 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31589561 0.86 MEN1 (0.71) MEN1KMT2AMYCIDO1POLB
SCHEMBL5246076 0.84 MEN1 (0.72) MEN1KMT2AMYCIDO1POLB
SCHEMBL300082 0.83 IDO1 (0.76) MEN1KMT2AMYCIDO1POLB
SCHEMBL25342279 0.82 MEN1 (0.54) MEN1KMT2AMYCIDO1POLB
SCHEMBL31054000 0.82 MEN1 (0.54) MEN1KMT2AMYCIDO1POLB
SCHEMBL300142 0.81 MEN1 (0.72) MEN1KMT2AMYCIDO1POLB
SCHEMBL5247559 0.80 MEN1 (0.65) MEN1KMT2AMYCIDO1POLB
SCHEMBL6836399 0.77 MEN1 (0.63) MEN1KMT2AMYCIDO1POLB
SCHEMBL315294 0.77 IDO1 (0.57) MEN1KMT2AMYCIDO1POLB
SCHEMBL14933668 0.75 TNF (0.66) MEN1KMT2AMYCIDO1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 US disclosed
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 US disclosed
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 US disclosed
EP-2774613-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma De Madrid (ES) 2014-09-10 EP disclosed
EP-2774613-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma De Madrid (ES) 2014-09-10 EP disclosed
WO-2013064714-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF MAPK1, MAPK4, MAPK8 MEN1 3940/4885KMT2A 3069/4885MYC 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.